TY - JOUR
T1 - Clinical characteristics of patients with spondyloarthritis in Japan in comparison with other regions of the world
AU - Kishimoto, Mitsumasa
AU - Yoshida, Kazuki
AU - Ichikawa, Naomi
AU - Inoue, Hisashi
AU - Kaneko, Yuko
AU - Kawasaki, Taku
AU - Matsui, Kazuo
AU - Morita, Mitsuhiro
AU - Suda, Masei
AU - Tada, Kurisu
AU - Takizawa, Naoho
AU - Tamura, Naoto
AU - Taniguchi, Atsuo
AU - Taniguchi, Yoshinori
AU - Tsuji, Shigeyoshi
AU - Haji, Yoichiro
AU - Rokutanda, Ryo
AU - Yanaoka, Haruyuki
AU - Cheung, Peter P.
AU - Gu, Jieruo
AU - Kim, Tae Hwan
AU - Luo, Shue Fen
AU - Okada, Masato
AU - Medina, Clementina López
AU - Molto, Anna
AU - Dougados, Maxime
AU - Kobayashi, Shigeto
AU - Van Der Heijde, Désirée
AU - Tomita, Tetsuya
N1 - Funding Information:
From the Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; Institute of Rheumatology, Tokyo Women’s Medical University; Department of Orthopedic Surgery, Juntendo University School of Medicine; Division of Rheumatology, Department of Rheumatology, Keio University School of Medicine, Tokyo; Department of Orthopedic Surgery, Shiga University of Medical Science, Shiga; Department of Rheumatology, Tonan Hospital, Hokkaido; Department of Orthopedic Surgery, Fujita Health University, Aichi; Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo; Department of Rheumatology, Chubu Rosai Hospital, Aichi; Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi; Department of Orthopedics, Osaka Minami Medical Center, Osaka; Department of Rheumatology, Daido Hospital, Aichi; Department of Internal Medicine, Juntendo University Koshigaya Hospital, Saitama; Department of Orthopedic Biomaterial Science, Osaka University Graduate School of Medicine, Osaka, Japan; departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; Division of Rheumatology, National University Hospital, Singapore; Division of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea; Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan; Hospital Universitario Reina Sofía/IMIBIC/University of Córdoba, Córdoba, Spain; Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris, France; INSERM Unit 1183, CRESS, Paris, France; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. This study was conducted under the umbrella of the International Society for Spondyloarthritis Assessment (ASAS) and the COMOSPA study was supported by the unrestricted grants from Pfizer, AbbVie, and UCB. M.K. received honoraria from AbbVie and Ayumi; K.Y. receives tuition support from Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA); A.M. has received research grants from Abbvie, Pfizer, and MSD. M. Kishimoto, MD, Immuno-Rheumatology Center, St. Luke’s
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Objective. To delineate clinical characteristics of patients with spondyloarthritis (SpA) in Japan in comparison to other areas of the world. Methods. Using the ASAS-COMOSPA (Assessment of Spondyloarthritis international Society–COMOrbidities in SPondyloArthritis) data, an international cross-sectional observational study of patients with SpA, we analyzed information on demographics, disease characteristics, comorbidities, and risk factors. Patients were classified by region: Japan, other Asian countries (China, Singapore, South Korea, Taiwan), and non-Asian countries (Europe, the Americas, Africa). Patient characteristics, including diagnosis and treatment, were compared. Results. Among 3984 patients included in the study, 161 were from centers in Japan, 933 from other Asian countries, and 2890 from other regions. Of patients with SpA in Japan, 42 (26.1%) had peripheral SpA, substantially more than in other countries. This trend was explained by the predominance of psoriatic arthritis (PsA) among Japanese patients with SpA. In contrast to the relatively low number in Japan, 54% of patients from other Asian countries had pure axial SpA (axSpA) without peripheral features. HLA-B27 testing, considered an integral part of the classification of axSpA, was performed in only 63.6% of Japanese patients with axSpA. More than half of Japanese patients with axSpA were classified using imaging criteria. Conclusion. In our study, there was a more substantial number of peripheral SpA cases observed in Japan compared to other parts of Asia and other regions of the world. Aside from ethnic differences, increasing recognition of PsA in Japan, as well as a potential underdiagnosis of axSpA due to the insufficient use of HLA-B27 testing, may partly explain regional discrepancies.
AB - Objective. To delineate clinical characteristics of patients with spondyloarthritis (SpA) in Japan in comparison to other areas of the world. Methods. Using the ASAS-COMOSPA (Assessment of Spondyloarthritis international Society–COMOrbidities in SPondyloArthritis) data, an international cross-sectional observational study of patients with SpA, we analyzed information on demographics, disease characteristics, comorbidities, and risk factors. Patients were classified by region: Japan, other Asian countries (China, Singapore, South Korea, Taiwan), and non-Asian countries (Europe, the Americas, Africa). Patient characteristics, including diagnosis and treatment, were compared. Results. Among 3984 patients included in the study, 161 were from centers in Japan, 933 from other Asian countries, and 2890 from other regions. Of patients with SpA in Japan, 42 (26.1%) had peripheral SpA, substantially more than in other countries. This trend was explained by the predominance of psoriatic arthritis (PsA) among Japanese patients with SpA. In contrast to the relatively low number in Japan, 54% of patients from other Asian countries had pure axial SpA (axSpA) without peripheral features. HLA-B27 testing, considered an integral part of the classification of axSpA, was performed in only 63.6% of Japanese patients with axSpA. More than half of Japanese patients with axSpA were classified using imaging criteria. Conclusion. In our study, there was a more substantial number of peripheral SpA cases observed in Japan compared to other parts of Asia and other regions of the world. Aside from ethnic differences, increasing recognition of PsA in Japan, as well as a potential underdiagnosis of axSpA due to the insufficient use of HLA-B27 testing, may partly explain regional discrepancies.
UR - http://www.scopus.com/inward/record.url?scp=85070955286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070955286&partnerID=8YFLogxK
U2 - 10.3899/jrheum.180412
DO - 10.3899/jrheum.180412
M3 - Article
C2 - 30770497
AN - SCOPUS:85070955286
VL - 46
SP - 896
EP - 903
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 8
ER -